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difference in effectiveness of drug therapy and surgery or between surgery types 
for carotid stenosis patients.
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Objectives: Comparative effectiveness research (CER) methods guides have 
recently been released by two main CER funding agencies, the Agency for Healthcare 
Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute 
(PCORI). We evaluated and compared these methods guides to identify consensus 
in recommended CER methodologies. MethOds: CER methods recommendations 
from each document were assessed and areas of overlap were identified. Results: 
The PCORI Methodology Report (November 2013) made 40 CER methods recommen-
dations. The AHRQ User Guide (January 2013) made 57 CER methods recommenda-
tions. These methods recommendations related to the following 10 methods topics: 
study protocol and design, patient-centeredness, heterogeneity of treatment effect 
(HTE), causal inference, diagnostic tests, systematic reviews, comparator selection, 
study variables, data concerns, and statistical analysis. Of the 57 specific recom-
mendations made in the AHRQ guide, 24 (42%) were also made in the PCORI guide. 
For example, both documents support identifying gaps in evidence, explaining 
specific impacts of the research, developing a formal study protocol, and assess-
ing the adequacy of data sources. Furthermore, these documents both support 
rigorous measurement and analysis of confounders, precisely defining exposures 
and outcomes, and pre-specification of data analysis plans. Both documents also 
supported the selection of appropriate comparators and identifying and assess-
ing participant subgroups. Non-overlapping recommendations mostly addressed 
more specific methodology topics and issues including missing data, data regis-
tries, data networks, and patient-centeredness. These unique recommendations 
highlight areas for further debate and discussion regarding best practices in CER 
methods. cOnclusiOns: Based upon our synthesis of CER methods recommenda-
tions, agreement was high between the AHRQ and PCORI guides. We identified a list 
of core CER recommendations based on the overlap of these two methods guides 
which may aid researchers in the conduct of CER.
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Objectives: Medical device utilization and price are often cited as major cost 
drivers of hospital care. Few sources quantify the specific % medical device spend 
(utilization x price) of hospital care. The purpose of this study was to assess the 
contribution of medical device spending in the hospital setting, as well as the impact 
of hospital facility type on medical device spending. MethOds: A third party ven-
dor, MOSS Adams (Seattle, WA) compiled data from the 2009 U.S. Healthcare Cost 
Report Information system (HCRIS). HCRIS data is reported by providers through 
Medicare Administrative Contractors. The cost report contains information such as 
facility characteristics, utilization data, cost and charges by cost center (all payers). 
5,452 hospitals reported medical device spending costs with total expenditures of 
approximately $681 billion dollars. Costs were divided into implant costs, billable 
supply costs, labor, capital, and all other costs including infrastructure. Total medical 
device costs were estimated from implant and billable supply costs. Stratification 
included teaching/non-teaching, sole-community/ non-sole, and urban/rural hospi-
tals. Results: Labor and other costs represented the largest expenditure, whereas 
total medical device costs represented 3.6% (median) of costs. Urban hospitals spent 
more than rural hospitals on medical devices (5.5% vs. 2.3%, p< 0.0001). Teaching 
hospitals also spent more than non-teaching hospitals on medical devices (6.2% 
vs. 3.1%, p< 0.0001). There were no differences in medical device spend for sole 
community/non-sole community hospitals (3.6% each). When reviewing a subset of 
hospitals (n= 644) reporting on implantable medical device use, median total medical 
device spend was 7.1% including 3.5% on medical device implants. cOnclusiOns: 
These data suggest that total spending on medical devices, including implantables 
in the hospital setting represents a small spend of overall hospital expenditures. 
Future studies should examine the role of medical device utilization in overall hos-
pital expenditures.
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Objectives: Transcatheter aortic valve implantation (TAVI) is a treatment option 
for patients with severe symptomatic aortic stenosis ineligible for surgical treat-
ment (AVR). However, the role of TAVI in patients who are potential surgical can-
didates remains controversial and its cost-effectiveness has only been assessed 
using data from one single randomized trial. We sought to estimate the cost-
utility of the two existing transfemoral TAVI modalities (Edwards SAPIEN (ES) and 
Objectives: To compare the post-cessation weight gain following the use of 
different FDA-approved smoking cessation medication strategies among obese 
smokers. MethOds: A retrospective cohort study was conducted using the 
General Electric (GE) electronic medical record database (2006 – 2011). The cohort 
consisted of obese adult smokers newly initiating use of an FDA-approved smok-
ing cessation medication. The outcome variable was weight change at 3, 6, or 12 
months following the first prescription. Descriptive analyses and t-tests were 
conducted to assess the frequency distribution of sample characteristics and their 
association with the post-cessation weight change. Multivariate linear regression 
models were carried out to identify predictors of weight change at 3, 6, and 12 
months after assessing the model assumptions, with the use of multiple impu-
tation to account for missing data for covariates. Results: The mean weight 
change was 1.14 (±17.26), 2.06 (±18.46), and 3.06 pounds (±20.78) at 3-, 6-, and 
12-month, respectively. Obese smokers who were prescribed varenicline had a 
mean weight gain of 1.18 (±16.75), 2.14 (±18.14), and 3.12 pounds (±20.89) for each 
follow up, while those who were prescribed bupropion had a mean weight gain 
of 0.23 (±25.90), 0.22 (±25.32), and 1.47 pounds (±17.50), respectively. Descriptive 
analysis showed that obese smokers taking bupropion had less weight gain than 
those taking varenicline at each follow up; however, this association was not 
statistically significant after accounting for all covariates (β = -1.16 [-3.84 – -1.53] 
month 3; β = -3.16 [-6.54 – -0.21] month 6; β = -0.18 [-3.92 – 3.55] month 12). 
Significant predictors of weight change included: being diagnosed with diabe-
tes, hyperlipidemia, taking weight-influencing medications, and smoked > = one 
cigarette/day. cOnclusiOns: While patients using bupropion gained slightly less 
weight compared to those using varenicline, type of smoking cessation medica-
tion was not a significant predictor of weight change in the multivariate linear 
regression model.
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Objectives: Several single arm phase III trials have recently completed or are cur-
rently ongoing in various HCV patient populations. The goal of this study is to use 
meta-analysis to determine the rates of sustained virologic response 24 weeks after 
treatment (SVR24) required for a new HCV treatment to declare superiority over 
standard of care (SOC) in the setting of a single arm trial where there is no network 
of treatment arms that can bridge between the new treatment and SOC. MethOds: 
We conducted a literature search for studies of standard dose peginterferon-alfa 
plus ribavirin (IFNα +R) as well as telaprevir (TPV) or boceprevir plus IFNα +R among 
HCV-infected adults and synthesized the results by performing a meta-analysis 
based on a Bayesian hierarchical model. We then introduce hypothetical single arm 
trials into the meta-analysis and determine the efficacy relative to SOC. Benchmarks 
are the SVR24 rates required to have at least a 95% probability of superiority to 
SOC. Results: Benchmarks for a new treatment studied in a single arm trial of 
400 patients relative to TPV+IFNα +R are 84%, 72%, and 54% in genotype 1a or 88%, 
78%, and 62% in genotype 1b across treatment naïve, previous partial respond-
ers, and previous null responders respectively. Benchmarks for a new treatment 
studied in a single arm trial of 200 treatment naive patients relative to IFNα +R are 
91%, 88%, and 69% in genotypes 2, 3, and 4 respectively. Benchmarks were insensi-
tive to the sample size of the single arm trial. cOnclusiOns: Our meta-analysis 
method extends indirect treatment comparison methodology to make comparative 
effectiveness inference for treatments studied in single arm phase III trials. Our 
broad based meta-analysis platform is flexible enough to make inference across 
patient populations.
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bAckgROund: Randomized clinical trials comparing surgery to drug therapy in 
newly diagnosed carotid stenosis patients, are less relevant today with advance-
ment in drug therapy and increased utilization. Effectiveness of surgery versus 
current drug therapy in carotid artery stenosis patients hasn`t been studied in real 
world practice. Objectives: Compare time to death and other cerebrovascular 
events in newly diagnosed patients treated with carotid endarterectomy (CEA), 
carotid stenting (CAS) or drug therapy MethOds: Patients were identified using 
the Humana dataset for the years 2007 – 2012. The date of first diagnosis of carotid 
stenosis is set as the patient’s index date if followed by a confirmatory carotid 
duplex ultrasound. An episode of treatment consisted of the 6 months prior to and 
12 months post index date. Propensity score matching was employed to match 
patients using drug therapy to surgery patients. Surgery patients using CAS or CEA 
were matched separately. Cox proportional hazards models and logistic regres-
sion were used to estimate the impact of surgery versus medications, and surgery 
type using only surgery patients. Outcomes were defined as time to death and 
time to stroke or other cerebrovascular event. Results: 103,703 newly diagnosed 
patients were identified over age 50. A total of 4921 patients received surgery of 
which 476 died (9.7%). Of the 98,782 patients who received only drug therapy, 
7395 died (7.4%). Initial Cox and logistic models of death using the propensity 
score matched samples found no statistically significant risk associated with 
surgery versus medical management. Similarly, we found no statistically 
significant effects of CAS vs CEA in patients treated with a surgical interven-
tion. cOnclusiOns: Current clinical studies suggest stand-alone drug ther-
apy as treatment of choice. Initial analysis of this study suggests no real world 
